Literature DB >> 12137195

Virolytic action of lipoprotein lipase on hepatitis C virus in human sera.

Reiner Thomssen1, Sigrid Bonk.   

Abstract

In most sera of hepatitis C virus (HCV)-infected patients beta-lipoproteins are bound to HCV RNA-carrying material, most often simultaneously with immunoglobulins (IgG, IgM) and sometimes additionally with high-density lipoproteins, forming complexes of low density (1.04-1.06 g/ml). To separate HCV particles from bound material, we tried to destroy the lipoprotein enzymatically by incubating HCV-positive human sera with lipoprotein lipase derived from Pseudomonas spp. (LPL-Ps). After this treatment, titers of HCV RNA in human sera (determined by a simple semiquantitative reverse transcription-PCR assay) were strongly reduced, regardless of whether primers of the NTR or NS5 region were used. Inactivation of HCV RNA could be inhibited by the addition of RNAguard to the serum-enzyme mixture. The lytic effect of the LPL-Ps preparation could be inhibited by tetrahydrolipstatin. Hence LPL-Ps seems to disrupt the HCV particle structure, including the putative core of the virus, and makes HCV RNA sensitive for RNase present in the reaction mixture. HBV was not destroyed by LPL-Ps. Porcine pancreatic lipase had no effect on HCV. The implications of these observations for the structure and biology of HCV and for its stability and inactivation in human sera are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12137195     DOI: 10.1007/s00430-001-0106-x

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  9 in total

1.  Interplay among cellular polarization, lipoprotein metabolism and hepatitis C virus entry.

Authors:  Ignacio Benedicto; Francisca Molina-Jiménez; Ricardo Moreno-Otero; Manuel López-Cabrera; Pedro L Majano
Journal:  World J Gastroenterol       Date:  2011-06-14       Impact factor: 5.742

Review 2.  Biochemistry and pathophysiology of intravascular and intracellular lipolysis.

Authors:  Stephen G Young; Rudolf Zechner
Journal:  Genes Dev       Date:  2013-03-01       Impact factor: 11.361

Review 3.  Hepatitis C virus-apolipoprotein interactions: molecular mechanisms and clinical impact.

Authors:  Emilie Crouchet; Thomas F Baumert; Catherine Schuster
Journal:  Expert Rev Proteomics       Date:  2017-06-30       Impact factor: 4.250

4.  Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry.

Authors:  Patrick Maillard; Marine Walic; Philip Meuleman; Farzin Roohvand; Thierry Huby; Wilfried Le Goff; Geert Leroux-Roels; Eve-Isabelle Pécheur; Agata Budkowska
Journal:  PLoS One       Date:  2011-10-21       Impact factor: 3.240

Review 5.  Potential cellular receptors involved in hepatitis C virus entry into cells.

Authors:  Daniel Favre; Beat Muellhaupt
Journal:  Lipids Health Dis       Date:  2005-04-19       Impact factor: 3.876

Review 6.  Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design.

Authors:  Florian Wrensch; Emilie Crouchet; Gaetan Ligat; Mirjam B Zeisel; Zhen-Yong Keck; Steven K H Foung; Catherine Schuster; Thomas F Baumert
Journal:  Front Immunol       Date:  2018-06-21       Impact factor: 8.786

7.  Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients.

Authors:  Søren U Nielsen; Margaret F Bassendine; Alastair D Burt; Caroline Martin; Wanna Pumeechockchai; Geoffrey L Toms
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

Review 8.  Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease.

Authors:  Daniel J Felmlee; Mohamed Lamine Hafirassou; Mathieu Lefevre; Thomas F Baumert; Catherine Schuster
Journal:  Viruses       Date:  2013-05-23       Impact factor: 5.048

Review 9.  Lipoprotein receptors and lipid enzymes in hepatitis C virus entry and early steps of infection.

Authors:  Eve-Isabelle Pécheur
Journal:  Scientifica (Cairo)       Date:  2012-12-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.